Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer - Rea, D; Gray, R; Bowden, S; Handley, K; Earl, H; Poole, C; Bates, T; Dewar, J; Raytor, Z; Lee, M (EUROPEAN JOURNAL OF CANCER, 2013)